Reprieve Cardiovascular is focused on improving outcomes for patients suffering from acute decompensated heart failure.
Reprieve Cardiovascular has raised $61.0M in total funding. The most recent round was Series B. The last funding was announced in August 2025.
Reprieve Cardiovascular's investors include Lightstone Ventures, Sante Ventures, Deerfield Management, Arboretum Ventures, Deerfield.
Reprieve Cardiovascular is headquartered in Milford, United States.
Reprieve Cardiovascular is focused on improving outcomes for patients suffering from acute decompensated heart failure.
Reprieve Cardiovascular is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Reprieve Cardiovascular — Funding & Investors." VCBacked, August 13, 2025, https://www.vcbacked.co/company/reprieve-cardiovascular. Accessed July 31, 2026.
VCBacked. (2025). Reprieve Cardiovascular — Funding & Investors. Retrieved July 31, 2026, from https://www.vcbacked.co/company/reprieve-cardiovascular
{{cite web |title=Reprieve Cardiovascular — Funding & Investors |url=https://www.vcbacked.co/company/reprieve-cardiovascular |website=VCBacked |access-date=July 31, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated